NLVP
ADXN

New Leaf Venture Partners’s Addex Therapeutics ADXN Stock Holding History

New Leaf Venture Partners’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,500
Closed -$40K – 18
2022
Q3 		$40K Hold
2,500
– – 0.02% 19
2022
Q2 		$58K Hold
2,500
– – 0.04% 21
2022
Q1 		$254K Hold
2,500
– – 0.13% 21
2021
Q4 		$315K Hold
2,500
– – 0.11% 22
2021
Q3 		$451K Hold
2,500
– – 0.13% 22
2021
Q2 		$478K Buy
+2,500
New +$508K 0.12% 19

Other funds holding ADXN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

New Leaf Venture Partners's ADXN Position: Q4 2022 in Review

New Leaf Venture Partners sold out of Addex Therapeutics (ADXN) in Q4 2022, closing a stake of 2,500 shares — an estimated $40K sold.

New Leaf Venture Partners first reported a position in ADXN in Q2 2021 and held it in 6 quarters. The position peaked at $478K in Q2 2021. 8 funds tracked by Wall St. Rank hold ADXN as of Q4 2022.

  • New Leaf Venture Partners reported no remaining Addex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • New Leaf Venture Partners sold 2,500 Addex Therapeutics shares in Q4 2022, an estimated $40K.
  • New Leaf Venture Partners first reported a position in Addex Therapeutics in Q2 2021 and held it in 6 quarters.
  • New Leaf Venture Partners's Addex Therapeutics position peaked at $478K in Q2 2021.
  • 8 funds tracked by Wall St. Rank held Addex Therapeutics as of Q4 2022.

Based on New Leaf Venture Partners's 13F filing for Q4 2022, filed 6 Feb 2023.